267 related articles for article (PubMed ID: 27288726)
1. Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy.
Jaffrès PA; Gajate C; Bouchet AM; Couthon-Gourvès H; Chantôme A; Potier-Cartereau M; Besson P; Bougnoux P; Mollinedo F; Vandier C
Pharmacol Ther; 2016 Sep; 165():114-31. PubMed ID: 27288726
[TBL] [Abstract][Full Text] [Related]
2. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
3. Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine.
Gajate C; Mollinedo F
Anticancer Agents Med Chem; 2014 May; 14(4):509-27. PubMed ID: 24628241
[TBL] [Abstract][Full Text] [Related]
4. Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria.
Mollinedo F; Fernández M; Hornillos V; Delgado J; Amat-Guerri F; Acuña AU; Nieto-Miguel T; Villa-Pulgarín JA; González-García C; Ceña V; Gajate C
Cell Death Dis; 2011 May; 2(5):e158. PubMed ID: 21593790
[TBL] [Abstract][Full Text] [Related]
5. Lipid rafts as major platforms for signaling regulation in cancer.
Mollinedo F; Gajate C
Adv Biol Regul; 2015 Jan; 57():130-46. PubMed ID: 25465296
[TBL] [Abstract][Full Text] [Related]
6. Lipid rafts and Fas/CD95 signaling in cancer chemotherapy.
Gajate C; Mollinedo F
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):274-83. PubMed ID: 21762074
[TBL] [Abstract][Full Text] [Related]
7. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.
Gajate C; Mollinedo F
Blood; 2007 Jan; 109(2):711-9. PubMed ID: 17003375
[TBL] [Abstract][Full Text] [Related]
8. Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids.
Castro BM; Fedorov A; Hornillos V; Delgado J; Acuña AU; Mollinedo F; Prieto M
J Phys Chem B; 2013 Jul; 117(26):7929-40. PubMed ID: 23738749
[TBL] [Abstract][Full Text] [Related]
9. New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis.
Girault A; Haelters JP; Potier-Cartereau M; Chantome A; Pinault M; Marionneau-Lambot S; Oullier T; Simon G; Couthon-Gourvès H; Jaffrès PA; Corbel B; Bougnoux P; Joulin V; Vandier C
Curr Cancer Drug Targets; 2011 Nov; 11(9):1111-25. PubMed ID: 21999627
[TBL] [Abstract][Full Text] [Related]
10. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells.
Gajate C; Gonzalez-Camacho F; Mollinedo F
PLoS One; 2009; 4(4):e5044. PubMed ID: 19352436
[TBL] [Abstract][Full Text] [Related]
11. Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells.
Alves ACS; Dias RA; Kagami LP; das Neves GM; Torres FC; Eifler-Lima VL; Carvalho I; de Miranda Silva C; Kawano DF
Curr Med Chem; 2018; 25(18):2082-2104. PubMed ID: 29332565
[TBL] [Abstract][Full Text] [Related]
12. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy.
Mollinedo F; Gajate C
Drug Resist Updat; 2006; 9(1-2):51-73. PubMed ID: 16687251
[TBL] [Abstract][Full Text] [Related]
13. ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor.
Mollinedo F; Gajate C; Martín-Santamaría S; Gago F
Curr Med Chem; 2004 Dec; 11(24):3163-84. PubMed ID: 15579006
[TBL] [Abstract][Full Text] [Related]
14. Edelfosine in membrane environment - the Langmuir monolayer studies.
Dynarowicz-Latka P; Hac-Wydro K
Anticancer Agents Med Chem; 2014 May; 14(4):499-508. PubMed ID: 24628234
[TBL] [Abstract][Full Text] [Related]
15. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis.
Gajate C; Del Canto-Jañez E; Acuña AU; Amat-Guerri F; Geijo E; Santos-Beneit AM; Veldman RJ; Mollinedo F
J Exp Med; 2004 Aug; 200(3):353-65. PubMed ID: 15289504
[TBL] [Abstract][Full Text] [Related]
16. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents.
Wagner BA; Buettner GR; Burns CP
Cancer Res; 1992 Nov; 52(21):6045-51. PubMed ID: 1394229
[TBL] [Abstract][Full Text] [Related]
17. Suppression of metastatic organ colonization and antiangiogenic activity of the orally bioavailable lipid raft-targeted alkylphospholipid edelfosine.
Alonso-Pérez V; Hernández V; Calzado MA; Vicente-Blázquez A; Gajate C; Soler-Torronteras R; DeCicco-Skinner K; Sierra A; Mollinedo F
Biomed Pharmacother; 2024 Feb; 171():116149. PubMed ID: 38266621
[TBL] [Abstract][Full Text] [Related]
18. 1-O-octadecyl-2-O-methylglycero-3-phosphocholine (Edelfosine) and cancer cell invasion: a short review.
Van Slambrouck S; Steelant WF
Anticancer Agents Med Chem; 2014 May; 14(4):539-44. PubMed ID: 24628232
[TBL] [Abstract][Full Text] [Related]
19. Surface-active properties of the antitumour ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (edelfosine).
Busto JV; Sot J; Goñi FM; Mollinedo F; Alonso A
Biochim Biophys Acta; 2007 Jul; 1768(7):1855-60. PubMed ID: 17543274
[TBL] [Abstract][Full Text] [Related]
20. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts.
Van der Luit AH; Budde M; Zerp S; Caan W; Klarenbeek JB; Verheij M; Van Blitterswijk WJ
Biochem J; 2007 Jan; 401(2):541-9. PubMed ID: 17049047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
